产品说明书

Obeticholic Acid

Print
Chemical Structure| 459789-99-2 同义名 : INT-747;6-ECDCA;Ocaliva.;6-Ethylchenodeoxycholic acid
CAS号 : 459789-99-2
货号 : A387805
分子式 : C26H44O4
纯度 : 98%
分子量 : 420.625
MDL号 : MFCD16621104
存储条件：

粉末 Sealed in dry,Room Temperature

液体 -20°C:3-6个月-80°C:12个月
溶解度 :

DMSO: 105 mg/mL(249.63 mM)，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

无水乙醇: 50 mg/mL(118.87 mM)，注意：无水乙醇开封后，易挥发，也会吸收空气中的水分，导致溶解能力下降，请避免使用开封较久的乙醇
动物实验配方：
生物活性
描述 The farnesoid X receptor (FXR) is an orphan member of the nuclear receptor superfamily that can be activated by small, lipophilic hormones. Obeticholic acid is a potent and selective FXR agonist with an EC50 value of 99 nM. It also showed potent FXR agonist activity in HuH7 cells with an EC50 value of 85 nM[3]. The treatment of rat hepatocytes with 1 μM obeticholic acid increased mRNA expression of small heterodimer partner and bile salt export pump. The exposure to obeticholic acid also led to 70 - 80% reduction of cholesterol 7α-hydroxylase, oxysterol 12β-hydroxylase, and Na+/taurocholate cotransporting peptide in rat hepatocytes[4]. The dosing of obeticholic acid at a rate of 3 µmol/kg/min completely reversed the impairment of bile flow and protected rats against lithocholic-induced liver cell injury[3].
细胞研究
细胞系 浓度 检测类型 检测时间 活动说明 数据源
CHO cells Function assay 5 h Agonist activity at human TGR5 expressed in CHO cells after 5 hrs by CRE-driven luciferase reporter gene assay, EC50=0.755 μM 17685603
COS1 cells Function assay Agonist activity at FXR expressed in COS1 cells by cell-based bioluminescence assay, EC50=99 nM 20014870
HeLa cells Function assay 24 h Agonist activity at human full length FXR expressed in HeLa cells cotransfected with pSG5-human RXR after 24 hrs by Dual-Glo luciferase reporter gene assay, EC50=0.16 μM 25934227
临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02654236 Alcohol Consumption Not Applicable Recruiting July 2019 United States, Indiana ... 展开 >> Indiana University Recruiting Indianapolis, Indiana, United States, 46202 Contact: Jennifer Lehman, RN    317-278-1872    jgeck@iu.edu    Contact: Megan Comerford, BS, MPH    3172789226    mcomerfo@iu.edu    Sub-Investigator: Naga Chalasani, MD          Principal Investigator: Suthat Liangpunsakul, MD          Sub-Investigator: David Crabb, MD 收起 <<
NCT00501592 Diabetes Mellitus, Type II ... 展开 >> Fatty Liver 收起 << Phase 2 Completed - United States, California ... 展开 >> Profil Institute for Clinical Research, Inc. Chula Vista, California, United States, 91911 UC San Diego VAMC San Diego, California, United States, 92161 United States, Texas Diabetes & Glandular Disease Research Associates, Inc. San Antonio, Texas, United States, 78229 United States, Virginia Virginia Commonwelath University Richmond, Virginia, United States, 23298 收起 <<
NCT00570765 Liver Cirrhosis, Biliary Phase 2 Completed - United States, Michigan ... 展开 >> Henry Ford Novi, Michigan, United States, 39450 United States, Texas Baylor College of Medicine Houston, Texas, United States, 77030 United States, Virginia McGuire DVAMC Richmond, Virginia, United States, 23219 United States, Washington Virginia Mason Medical Center Seattle, Washington, United States, 98101 Austria Karls-Franzens University Graz, Austria, A8036 Canada, Alberta University of Alberta Edmonton, Alberta, Canada, T6G 2C8 Canada, Ontario University of Toronto Toronto, Ontario, Canada, M5T 2S8 Canada, Quebec Centre de Recherche du CHUM / University of Montreal Montreal, Quebec, Canada, H2X 1P1 France Hopital de l'Hotel Dieu Lyon, France, 69288 Hopital Saint-Antoine Paris, France, 75012 Germany Johann Wolfgang Goethe University Frankfurt, Germany, 60590 University Medical Centre Hamburg-Eppendorf Hamburg, Germany, D20246 Medical School of Hannover Hannover, Germany, 30623 University of Munich Munich, Germany, D81377 Spain Hospital Clinic i Provincial Barcelona, Spain, 08036 United Kingdom Queen Elizabeth Medical Center Edgbaston, Birmingham, United Kingdom, B15 2TH Royal Free Hospital Hampstead, London, United Kingdom, NW3 2QG John Radcliffe Hospital Headington, Oxford, United Kingdom, OX3 9DU Royal Infirmary Edinburgh, United Kingdom, EH16 4SA University Upon Tyne/Newcastle Newcastle Upon Tyne, United Kingdom, NE2 4HH 收起 <<
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.89mL

2.38mL

1.19mL

23.77mL

4.75mL

2.38mL
参考文献

[1]Verbeke L, Farre R, et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology. 2014 Jun;59(6):2286-98.

[2]Pellicciari R, Fiorucci S, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002 Aug 15;45(17):3569-72.

[3]Pellicciari R, Fiorucci S, Camaioni E, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002;45(17):3569-3572. doi:10.1021/jm025529g

[4]Fiorucci S, Clerici C, Antonelli E, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005;313(2):604-612. doi:10.1124/jpet.104.079665